News Grower

Independent coverage of AI, startups, and technology.

Ars Technica May 6, 2026 at 16:19 Big Tech Stable Warm

FDA vaccine studies censored by Trump admin after finding benefits of shots

FDA has suppressed studies on COVID-19 vaccines and Shingrix, a shingles vaccine.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Beth Mole Original source
FDA vaccine studies censored by Trump admin after finding benefits of shots

Despite Health Secretary Robert F. Kennedy's pledge to provide "radical transparency," the agencies under his control continue to suppress scientific research that conflicts with his anti-vaccine agenda. On Tuesday, The New York Times reported confirmation from the Department of Health and Human Services that the Food and Drug Administration had blocked the publication of studies showing the safety and efficacy of vaccines against COVID-19 and shingles. The revelation follows a report from The Washington Post last month that the Centers for Disease Control and Prevention scrapped a scientifically vetted study previously scheduled for publication that found COVID-19 vaccines sharply cut the risk of emergency care and hospitalization among healthy adults. The study was ultimately rejected by Kennedy's acting CDC director, who claimed to have concerns about the study's methodology. Similarly at the FDA, two studies on COVID-19 vaccines by agency scientists were accepted for publication at medical journals, according to the Times. But unnamed FDA officials directed the agency scientists to withdraw the studies. While a preliminary abstract of one of the studies presented at a conference last fall remains online, the Times obtained a copy of the full manuscript, the conclusion of which reads, "Given the available evidence, FDA continues to conclude the benefits of vaccination outweigh the risks."Read full article Comments

Stay on the signal

Follow FDA vaccine studies censored by Trump admin after finding benefits of shots

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, COVID-19, and FDA, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 23, 2026 at 22:30 Ars Technica

White House drastically shortens deadline for dropping quantum-vulnerable crypto

Order warns of national security risks if post-quantum cryptography isn't adopted in time.

Jun 23, 2026 at 22:07 Ars Technica

US's climate.gov site, taken down by Trump, relaunched by nonprofit

Climate.us has now restored everything taken down by the government.

Jun 23, 2026 at 20:43 Ars Technica

Odd police video shows drone removing knife from motionless suspect

Promo video comes as more US police departments fly drones as first responders.

Jun 23, 2026 at 18:19 Ars Technica

A curious crossover: The Toyota C-HR review

Although it's on the smaller side, this electric vehicle is not very chill.

Jun 23, 2026 at 17:59 Ars Technica

ABC asks viewers to protest FCC attempt to "control who is allowed" on The View

"The FCC wants to control who is allowed on the show," ABC ad tells viewers.

May 6, 2026 at 16:19 Ars Technica

FDA vaccine studies censored by Trump admin after finding benefits of shots

FDA has suppressed studies on COVID-19 vaccines and Shingrix, a shingles vaccine.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page